DS04 - Vie, santé et bien-être

Microsystem based test device for the Global assessment of primary HaemOSTasis with flowing whole blood – GHOST

Submission summary

Von Willebrand disease (vWD) is a blood disorder in which blood does not clot properly. vWD occurs with equal frequency among men and women, affecting up to 1% of the general population. Between 2012 and 2016, more than 14600 men, women, and children were seen at hemophilia treatment centers for treatment of vWD. Blood contains many proteins that help the body stop bleeding and one of these proteins is called the von Willebrand factor (vWF). People with vWD either have a low level of vWF in their blood or the vWF protein doesn’t work the way it should. Haemostasis, the human body's response to blood vessel injury and bleeding, involves a coordinated effort between platelets and numerous blood clotting proteins, resulting in the formation of a blood clot and subsequent stopping of the bleed. Its initial step is primary haemostasis which results in a platelet plug and precedes the formation of blood clot closing the vascular lesions. This process requires a precise equilibrium and any deviation can lead to haemorrhages on one side or platelet deposits and thrombosis on another side. Therefore, a number of parameters should be controlled in order to monitor the haemostasis: circulating platelets, the plasma vWF and the state of vascular walls, that is, more specifically, the collagen exposed in case of vascular damage or atherosclerotic plaque rupture. Most of the currently available devices for primary haemostasis investigation operating with flowing whole blood are for research use only. Those adapted for clinical practice have several limitations: they do not reproduce rheological conditions of blood in vivo the reproducibility of measurements is insufficient and a substantial amount of blood is required. This project aims at designing and fabricating an innovative global test of primary haemostasis operating with flowing whole blood. Through this proof of concept, we intend to improve the pathology evaluation in order to manage patients with bleeding risk or under antiplatelets therapy. This device will contain an immobilized recombinant collagen-like proteins and will operate with flowing whole blood under realistic rheological conditions. A multi-parameter acoustic biosensor will be integrated to perform real time measurements of pressure, blood flow properties and interactions between collagen and platelets. The detection and characterization of such interactions will provide information on each step of primary haemostasis and determine the overall impact of all blood components (collagen-like, platelets, vWF) involved in the process. In summary, this innovative microsystem based test proposes to investigate primary haemostasis as a whole, in clinical situation, and using patient’s whole blood.

Project coordination

Thérèse LEBLOIS (Franche-Comté Electronique Mécanique Thermique et Optique- Sciences et Technologies)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CHU Dijon Centre Hospitalier Universitaire de Dijon: Service Hématologie Biologique
NVH NVH MEDICINAL
FEMTO-ST Franche-Comté Electronique Mécanique Thermique et Optique- Sciences et Technologies
EFS-BFC EFS - Etablissement Français du Sang

Help of the ANR 449,792 euros
Beginning and duration of the scientific project: - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter